Home › Therapeutic areas › Neurology › Myasthenia Gravis

Myasthenia Gravis (7 companies)

Companies with an active program in Myasthenia Gravis.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
CABA Cabaletta Bio DermatologyImmunology+2 Rare 1 Phase 2 $220M 8
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 $187M 4
IMVT Immunovant ImmunologyNeurology Rare 1 Phase 3 $6.87B 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
NKTX Nkarta ImmunologyNeurology+1 Rare 1 Phase 1 $89.6M 8
TGTX Tg Therapeutics Neurology Rare 2 Approved $9.48B 6
VOR Vor Biopharma ImmunologyNeurology Rare 1 Phase 3 $1.12B 2